These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 36725884)
21. The path to the clinic: a comprehensive review on direct KRAS Kwan AK; Piazza GA; Keeton AB; Leite CA J Exp Clin Cancer Res; 2022 Jan; 41(1):27. PubMed ID: 35045886 [TBL] [Abstract][Full Text] [Related]
23. Development and Preclinical Evaluation of Radiolabeled Covalent G12C-Specific Inhibitors for Direct Imaging of the Oncogenic KRAS Mutant. Zhang Z; Wang X; Ye J; Liu H; Fang J; Zhang M; Li Y; Huang J; Zhang D; Wang J; Zhang X Mol Pharm; 2021 Sep; 18(9):3509-3518. PubMed ID: 34410132 [TBL] [Abstract][Full Text] [Related]
24. Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy. Holderfield M; Lee BJ; Jiang J; Tomlinson A; Seamon KJ; Mira A; Patrucco E; Goodhart G; Dilly J; Gindin Y; Dinglasan N; Wang Y; Lai LP; Cai S; Jiang L; Nasholm N; Shifrin N; Blaj C; Shah H; Evans JW; Montazer N; Lai O; Shi J; Ahler E; Quintana E; Chang S; Salvador A; Marquez A; Cregg J; Liu Y; Milin A; Chen A; Ziv TB; Parsons D; Knox JE; Klomp JE; Roth J; Rees M; Ronan M; Cuevas-Navarro A; Hu F; Lito P; Santamaria D; Aguirre AJ; Waters AM; Der CJ; Ambrogio C; Wang Z; Gill AL; Koltun ES; Smith JAM; Wildes D; Singh M Nature; 2024 May; 629(8013):919-926. PubMed ID: 38589574 [TBL] [Abstract][Full Text] [Related]
25. KRAS Laurent PA; Milic M; Quevrin C; Meziani L; Liu W; Morel D; Signolle N; Clémenson C; Levy A; Mondini M; Deutsch E J Transl Med; 2023 Oct; 21(1):773. PubMed ID: 37907934 [TBL] [Abstract][Full Text] [Related]
26. Epithelial-to-Mesenchymal Transition is a Cause of Both Intrinsic and Acquired Resistance to KRAS G12C Inhibitor in KRAS G12C-Mutant Non-Small Cell Lung Cancer. Adachi Y; Ito K; Hayashi Y; Kimura R; Tan TZ; Yamaguchi R; Ebi H Clin Cancer Res; 2020 Nov; 26(22):5962-5973. PubMed ID: 32900796 [TBL] [Abstract][Full Text] [Related]
27. Activity and resistance to KRAS Ye W; Lu X; Qiao Y; Ou WB Biochim Biophys Acta Rev Cancer; 2024 May; 1879(3):189108. PubMed ID: 38723697 [TBL] [Abstract][Full Text] [Related]
28. Ganoderma microsporum immunomodulatory protein combined with KRAS Hua WJ; Hwang WL; Yeh H; Lin ZH; Hsu WH; Lin TY Int J Biol Macromol; 2024 Feb; 259(Pt 2):129291. PubMed ID: 38211909 [TBL] [Abstract][Full Text] [Related]
29. A Breakthrough Brought about by Targeting KRAS Ning W; Yang Z; Kocher GJ; Dorn P; Peng RW Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053550 [TBL] [Abstract][Full Text] [Related]
31. An integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancer. Wang H; Lv Q; Xu Y; Cai Z; Zheng J; Cheng X; Dai Y; Jänne PA; Ambrogio C; Köhler J EBioMedicine; 2019 Nov; 49():106-117. PubMed ID: 31668570 [TBL] [Abstract][Full Text] [Related]
32. Discovery of highly potent and selective KRAS Yang N; Fan Z; Sun S; Hu X; Mao Y; Jia C; Cai X; Xu T; Li B; Li Y; Han L; Wei T; Qian X; Qin W; Li P; Zheng Z; Li S Eur J Med Chem; 2023 Dec; 261():115857. PubMed ID: 37852032 [TBL] [Abstract][Full Text] [Related]
33. Inhibitors of the GTPase KRAS Xu Q; Zhang G; Liu Q; Li S; Zhang Y Expert Opin Ther Pat; 2022 May; 32(5):475-505. PubMed ID: 35062845 [TBL] [Abstract][Full Text] [Related]
34. Discovery of novel coumarin-based KRAS-G12C inhibitors from virtual screening and Rational structural optimization. Shi JT; Hou SJ; Cheng L; Zhang HJ; Mu HX; Wang QS; Wang ZY; Chen SW Bioorg Chem; 2024 Jul; 148():107467. PubMed ID: 38772290 [TBL] [Abstract][Full Text] [Related]
35. Adagrasib, a KRAS G12C inhibitor, reverses the multidrug resistance mediated by ABCB1 in vitro and in vivo. Zhang Y; Li C; Xia C; Wah To KK; Guo Z; Ren C; Wen L; Wang F; Fu L; Liao N Cell Commun Signal; 2022 Sep; 20(1):142. PubMed ID: 36104708 [TBL] [Abstract][Full Text] [Related]
36. Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRAS Ryan MB; Fece de la Cruz F; Phat S; Myers DT; Wong E; Shahzade HA; Hong CB; Corcoran RB Clin Cancer Res; 2020 Apr; 26(7):1633-1643. PubMed ID: 31776128 [TBL] [Abstract][Full Text] [Related]
37. Inhibition of RAS: proven and potential vulnerabilities. Zuberi M; Khan I; O'Bryan JP Biochem Soc Trans; 2020 Oct; 48(5):1831-1841. PubMed ID: 32869838 [TBL] [Abstract][Full Text] [Related]
38. Discovery of ARS-1620 analogs as KRas G12C inhibitors with high in vivo antitumor activity. Zhao H; Li L; Liu J; Mai R; Chen J; Chen J Bioorg Chem; 2022 Apr; 121():105652. PubMed ID: 35158284 [TBL] [Abstract][Full Text] [Related]
39. Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers. Hao HX; Wang H; Liu C; Kovats S; Velazquez R; Lu H; Pant B; Shirley M; Meyer MJ; Pu M; Lim J; Fleming M; Alexander L; Farsidjani A; LaMarche MJ; Moody S; Silver SJ; Caponigro G; Stuart DD; Abrams TJ; Hammerman PS; Williams J; Engelman JA; Goldoni S; Mohseni M Mol Cancer Ther; 2019 Dec; 18(12):2368-2380. PubMed ID: 31439712 [No Abstract] [Full Text] [Related]
40. Research progress on small molecule inhibitors targeting KRAS G12C with acrylamide structure and the strategies for solving KRAS inhibitor resistance. Jiang Z; Li Y; Zhou X; Wen J; Zheng P; Zhu W Bioorg Med Chem; 2024 Feb; 100():117627. PubMed ID: 38310752 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]